JP2023553117A5 - - Google Patents
Info
- Publication number
- JP2023553117A5 JP2023553117A5 JP2023535012A JP2023535012A JP2023553117A5 JP 2023553117 A5 JP2023553117 A5 JP 2023553117A5 JP 2023535012 A JP2023535012 A JP 2023535012A JP 2023535012 A JP2023535012 A JP 2023535012A JP 2023553117 A5 JP2023553117 A5 JP 2023553117A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- infection
- treatment
- recombinant protein
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122593P | 2020-12-08 | 2020-12-08 | |
| US63/122,593 | 2020-12-08 | ||
| US202163271444P | 2021-10-25 | 2021-10-25 | |
| US63/271,444 | 2021-10-25 | ||
| PCT/US2021/062168 WO2022125523A1 (en) | 2020-12-08 | 2021-12-07 | Manufacture of granulocyte macrophage-colony stimulating factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553117A JP2023553117A (ja) | 2023-12-20 |
| JP2023553117A5 true JP2023553117A5 (https=) | 2024-12-17 |
Family
ID=81974806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535012A Pending JP2023553117A (ja) | 2020-12-08 | 2021-12-07 | 顆粒球マクロファージコロニー刺激因子の製造 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240043486A1 (https=) |
| EP (1) | EP4259774A4 (https=) |
| JP (1) | JP2023553117A (https=) |
| CA (1) | CA3201327A1 (https=) |
| WO (1) | WO2022125523A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| EP1318834A2 (en) * | 2000-09-12 | 2003-06-18 | Genetrol Biotherapeutics, Inc. | Compositions comprising mixtures of human cytokines and methods of producing the same |
| CN101031323A (zh) * | 2004-07-16 | 2007-09-05 | 尼克塔治疗亚拉巴马公司 | Gm－csf部分与聚合物的缀合物 |
| EP2044203B1 (en) * | 2006-07-14 | 2013-10-09 | Novozymes, Inc. | Methods for increasing expression of genes in a fungal cell |
| JP2016513478A (ja) * | 2013-03-15 | 2016-05-16 | ジェネンテック， インコーポレイテッド | 細胞培養培地及び抗体を産生する方法 |
| WO2015095809A1 (en) * | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| WO2015143512A2 (en) * | 2014-03-23 | 2015-10-01 | Advantech Bioscience Farmacêutica Ltda. | Enhancement of recombinant protein expression with copper |
-
2021
- 2021-12-07 US US18/265,508 patent/US20240043486A1/en active Pending
- 2021-12-07 JP JP2023535012A patent/JP2023553117A/ja active Pending
- 2021-12-07 WO PCT/US2021/062168 patent/WO2022125523A1/en not_active Ceased
- 2021-12-07 EP EP21904233.0A patent/EP4259774A4/en active Pending
- 2021-12-07 CA CA3201327A patent/CA3201327A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality | |
| Akbari et al. | Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia | |
| Liu et al. | Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome | |
| US20230084300A1 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| Cancio et al. | Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies | |
| Leyfman et al. | Potential immunotherapeutic targets for hypoxia due to COVI-Flu | |
| US20230181637A1 (en) | Nk cells and uses thereof for treatment of microbial infections | |
| CA3211351A1 (en) | Populations of enriched regulatory t cells and methods for producing same | |
| JP2024524485A (ja) | 造血幹・前駆細胞からの形質細胞様樹状細胞のｃｇｍｐに準拠した作製及び増殖 | |
| JP2025501746A5 (https=) | ||
| CA3211348A1 (en) | Compositions comprising regulatory t cells and methods of using the same | |
| Maurya et al. | Novel stem cells and nucleic acid-based vaccine trials against viral outbreak: a systematic evaluation during COVID-2019 pandemic | |
| JP2023553117A5 (https=) | ||
| Malkan et al. | Hematological aspects of the COVID-19 syndrome. | |
| Yakar et al. | The effect of tocilizumab on severe COVID-19 infection: Review of current evidence. | |
| JP2023521671A (ja) | Ｃｏｖｉｄ－１９感染症に対する幹細胞免疫調節療法 | |
| JP2023547883A5 (https=) | ||
| US20230127499A1 (en) | Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus | |
| Krivoshlykova et al. | Serum concentrations of pro-and anti-inflammatory cytokines in Wistar rats subjected to immobilization stress and treated with Tuftsin-pro-Gly-pro peptide | |
| WO2022056092A1 (en) | Methods of treating viral infection | |
| CN115484959A (zh) | 用于治疗炎症的3-氮杂-双环[3.2.1]辛烷羧酸及其衍生物 | |
| del Toro-Arreola et al. | NK cells at the crossroads in COVID-19: a question of timing | |
| Kalyuzhin et al. | Effect of Tilorone on the Dynamics of Viral Load and the Levels of Interferons and Interleukin-1β in the Lung Tissue and Blood Serum of Mice with Experimental Influenza | |
| Li | Advances in the study of cytokine storm mechanisms in pneumonia: An example of IL-6 and IL-33 | |
| Gu et al. | The promise of mesenchymal stem cells therapy for acute respiratory distress syndrome caused by COVID-19 |